Antibacterial Agents TRIZ Cases

Controlled evaporation removes selected volatile fractions from essential oil, concentrating activity against bacterial and fungal strains.

Separating antigen recognition from C1q recruitment addresses antibody-binding density and geometry limits on complement-mediated killing.

Multiple rhamnose molecules linked to antibodies recruit immune responses at cancer and pathogen targets while addressing resistance mechanisms.

Error-prone PCR and fermentation in Trichoderma reesei produce stable, low-hemolysis TrSub for feed additive applications.

Selective N-glycan trimming exposes conserved SARS-CoV-2 epitopes while preserving tertiary structure for broader variant protection.

A dual regimen pairs sirolimus with tetracyclines to manage immune response and block amyloid and prion protein formation in animals.

Omadacycline penetrates infected cells and lung tissue to support long-term mycobacterial treatment with fewer gastrointestinal side effects.

Kinetic isotope substitution slows secnidazole metabolism, extending its elimination half-life for lower-dose bacterial vaginosis treatment.

Modified furin cleavage sites help recombinant proteins regulate free TGF-β growth factor release while preserving signaling control.

Existing vaccines protect against serotype b but lack cross-protection; saccharide-carrier conjugates target H. influenzae serotypes a–f.

Poorly tolerated NTM therapies are addressed with nebulized liposomal amikacin that concentrates aminoglycoside delivery in the lungs.

Drug efflux pumps weaken antibiotics against resistant Gram-negative bacteria; piperazine derivatives inhibit them and restore combination activity.

Targeted cdtR mutations, including a 69-base pair deletion, reduce toxin expression while preserving gut colonization for protection against wildtype infection.

Monovalent TCRs can lack pMHC avidity; IgM or IgA multimerization creates multivalent binders for detection and immune modulation.

Mature P. aeruginosa biofilms resist conventional antibiotics; NAC disrupts the matrix so colistin can penetrate and eradicate embedded cells.

Varying aryl and other substituents around the core addresses limited scaffold activity with broad antifungal, antitubercular, antimalarial, and antitumor effects.

Microbiome sequencing compares the patient with relatives, affected peers, and pre-condition samples to guide transplantation and restore gastrointestinal balance.

CRISPR-Cas genome cutting targets microbial DNA to support rapid acute infection treatment with less frequent dosing.

This 8-residue amphiphilic AMP disrupts PSA membranes and causes calcium leakage, with a reported MIC of 3.13 μg/mL and low hemolysis.

Peptide compounds bind menaquinone directly, disrupt bacterial membranes, and inhibit multidrug-resistant bacteria, including M. tuberculosis.

Engineered LL-37-derived peptides disrupt bacterial membranes and inhibit resistance development in antibiotic-resistant biofilms.

Probiotic, honey, and other natural ingredients disperse pathogenic biofilms while supporting local immunity without antibiotic treatment.

Long NTM regimens with poor outcomes are addressed by combining epetraborole and ethambutol for potential treatment synergy.

Maceration followed by controlled heating coagulates watercress proteins, separating a liquid fraction for urease inhibitor extraction.

Beta-lactamase production can disable cefepime; crystalline boron-containing inhibitor forms support stable injectable treatment of resistant infections.

Antimicrobial peptides use alternative membrane-disruption mechanisms to target resistant bacteria and reduce biofilm formation.

C-Type Lectin domains help liposomes bind pathogen antigens, improving targeting while lowering drug exposure to animal cells.

By activating TRPA1 with fear-odor compounds, this case induces hypothermia, hypometabolism, and anti-inflammatory responses without cooling equipment.

Existing β-lactamase inhibitors can miss Class D and metallo-β-lactamases; intravenous Compound A with meropenem enhances activity against resistant bacteria.

Fusion proteins use half-life extension domains, anionic blocks, and cleavable linkers to activate peptides at disease sites and limit off-target toxicity.

Phosphate copolymers suppress pathogen virulence factors for infection treatment without significantly reducing beneficial bacteria.

A barrier-based separation process isolates PEGylated IL-2 by binding site, supporting IL-2Rβγ selectivity and fewer adverse reactions.

Purified bacteriophage compositions target bacterial infections while removing harmful impurities and reducing the inflammatory response.

Unfractionated Croton lechleri latex uses multiple natural compounds for broad antibacterial coverage in infected or colonized skin.

Single-domain antibodies can degrade in the stomach; a linked two-peptide construct preserves binding to pathogen components and toxins.

An ambulatory pump delivers tailored terlipressin to manage ascites, reduce paracentesis frequency, and support renal function without hospitalization.

Targeting MDR and XDR bacteria, cysteine-substituted peptide variants offer an antimicrobial option when standard antibiotics fail.

Species-specific fusion proteins target Ehrlichia antibodies to improve E. ewingii identification despite cross-reactivity in serologic tests.

NHDC and peppermint oil are combined in poultry or swine feed to address weak in vivo results and reduce Campylobacter jejuni carriage.

Highly hydrophobic nosiheptide has low solubility and stability; PEGylated liposomes improve compatibility for antibacterial use.

Variable LPS and capsular antigens limit broad immunity; inactivated LPS-deficient cells present conserved OMPs for cross-protection.

Chain-length and substituent tuning improves DNA/RNA binding to pathogens while increasing selectivity over host cells.

Measuring DPP3 and pro-adrenomedullin supports early refractory shock prediction and guides therapeutic interventions.

Zastaprazan helps prevent NSAID-induced peptic ulcers and recurrence during long-term therapy without changing NSAID pharmacokinetic profiles.

ISVD-based GITR agonists address uncertain immunotherapy efficacy with EC50 values of 200 pM or less to activate T cells and inhibit tumors.

By binding PACAP before receptor activation, humanized antibodies aim to reduce vasodilation, photophobia, and neuronal activation in migraine.

A clay complex delivers non-absorbable antibiotic locally to gastric mucosa, targeting resistant H. pylori and limiting systemic exposure.

Protease-specific peptide cleavage releases masking moieties from antibody constructs for targeted therapeutic or diagnostic activation.

Universal linker chemistry supports multiple drug attachments while controlling drug-to-antibody ratios for more consistent ADC batches.

A spiro-structured Teixobactin analogue addresses resistant Gram-positive bacteria and Mycobacterium tuberculosis through a distinct antibacterial mechanism.

CRISPR-edited bacteriophage mutants target Propionibacterium acnes with high specificity.

MnTE-2-PyP porphyrin agent prevents erectile dysfunction and incontinence following pelvic radiation treatment.

Engineered bacteria produce vesicles displaying capsular polysaccharides, enabling vaccines against Gram-positive pathogens.

Carbonyldiimidazole catalyzes a one-pot synthesis yielding 68% of the target compound, overcoming drug resistance in gram-positive and gram-negative bacteria.

Antibodies targeting BTLA resolve the contradiction between stimulating T cell activation and maintaining immune defense against pathogens.

Targeting the VEGF pathway with inhibitors reduces pulmonary edema and inflammatory responses in hypoxia-related diseases.

Eubacterium contortum bacterial compositions reduce cytokine levels and disease severity by targeting the IL-17 and Th17 pathways in autoimmune conditions.

Genetic mutations in aroC, guaBA, and clpX reduce virulence while stabilized plasmids maintain antigen expression for safe oral immunization.

Recombinant bacteria deliver aquaporin peptides via microencapsulated bait to suppress tick populations without chemical acaricides.

A sticky soft gel delivers vaccine beadlets that adhere to poultry feathers.

Antibody molecule-drug conjugates bind lipopolysaccharides on Gram-negative bacteria to deliver antimicrobial peptides, reducing antibiotic resistance.

Enzyme compositions degrade feed antigens to lower immunological stress, improving growth performance.

Additive manufacturing embeds antibiotics in polymeric implants, preventing solvent-based coating failure and ensuring sustained protection against infection.

Amphiphilic coatings on calcium sulfate granules sustain antibiotic release over days to resolve rapid elution bottlenecks in osteomyelitis treatment.

Lolamycin inhibits the LolCDE complex to treat Gram-negative infections while sparing the gut microbiome.

A DNA expression vector directs diphtheria toxin fusion proteins to the periplasmic space for proper folding and secretion.

Probiotic-based topical sanitizer uses competitive exclusion to detach adherent pathogens while maintaining skin microbiome balance.

Haptoglobin subunits reduce hypoxia-induced delays in chronic wounds by enhancing oxygen content, fibroblast proliferation, and bacterial inhibition.

Hydrophilic nanostructured antibiotics selectively disrupt bacterial membranes through electrostatic interactions.

The AS-hepc3(48-56) peptide from Acanthopagrus schlegelii exhibits strong activity against drug-resistant pathogens.

Substituted heterocyclic compounds inhibit 11β-HSD1, reducing glucocorticoid levels and improving insulin sensitivity in metabolic disorders.

Isoindoline compounds reduce side effects and overcome drug resistance in refractory cancer therapies.

Formula I compounds target the Hsp90 ATP-binding site to indirectly inhibit topoisomerase II, reducing side effects and resistance.

Polymeric carriers extend peptide half-life by controlling hydrolytic release, addressing renal clearance challenges in cirrhosis and septic shock treatments.

Honaucin A compounds disrupt bacterial quorum sensing to prevent biofilm formation.

Hypertonic suspension base prevents active ingredient leaching from coated cores during storage, ensuring stable extended release profiles.

ORF2086 proteins provide broad protection against multiple meningococcal strains without requiring complex multi-component formulations.

Chemically bonding antibiotics to implant substrates via chelating mechanisms releases high local concentrations upon infection triggers.

Polyamine derivative medicinal salts antagonize multiple pathogen-associated molecular patterns.

Radezolid topical formulations address skin irritation and dryness from conventional treatments by substituting salicylic acid with oxazolidinone antibiotics.

Tuning hydrophobic side chains in cationic polycarbonates resolves the trade-off between killing microbes and damaging mammalian cells.

A one-step formulation uses extra-genomic nonsense RNA carrier molecules to stabilize nucleic acids during ambient transport.

Extracted outer membrane carbohydrates replace live bacteria in a combination vaccine, resolving manufacturing complexity while maintaining immunity efficacy.

Segmented DVD structures with optimized peptide linkers resolve molecular heterogeneity in bispecific antibody manufacturing.

Sugar-based surfactant microemulsions stabilize water-insoluble ingredients via nanodroplets, preventing phase separation and reducing skin irritation.

Truncated CyaA vectors deliver negatively charged antigens into target cells, resolving acidic charge interference that blocks translocation.

Transduction particles deliver nucleases to kill resistant B2 E. coli without disturbing the microbiome.

A piperacillin sodium and sulbactam sodium cocrystal formulation enhances drug stability through controlled crystallization.